Postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium.
In honor of Hispanic Heritage Month, this week’s episode of The Cancer Letter Podcast features three oncology leaders whose research focuses on identifying and solving health disparities specifically in the Latinx community.
